Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer.
Einstein (Sao Paulo)
; 20: eGS6655, 2022.
Article
in En
| MEDLINE
| ID: mdl-35544899
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Breast Neoplasms
Type of study:
Health_economic_evaluation
/
Prognostic_studies
Limits:
Female
/
Humans
Country/Region as subject:
America do norte
Language:
En
Journal:
Einstein (Sao Paulo)
Year:
2022
Document type:
Article
Affiliation country:
Brazil